GCLabs

Search for Test Items

Myelodysplastic Syndromes(MDS) / Myeloproliferative Neoplasm(MPN) Panel

GC Labs code	Q988	Test Field	Human genetics
Compulsory forms	Oncology requisition and consent form, GC Genome Informed consent for genetic testing

GC Labs code

Q988

Test Field

Human genetics

Compulsory forms

Oncology requisition and consent form, GC Genome Informed consent for genetic testing

Information

Test method	NGS (Next generation sequencing)
Specimen (mL)	EDTA WB 3.0
Specimen storage	Refrigerated
Specimen stability	Ambient (1 day), Refrigerated (3 days)
Test schedule	Mon-Fri
Analytical time (day)	14

Test method

NGS (Next generation sequencing)

Specimen (mL)

EDTA WB 3.0

Specimen storage

Refrigerated

Specimen stability

Ambient (1 day), Refrigerated (3 days)

Test schedule

Mon-Fri

Analytical time (day)

Reference range/Unit	[Whole Blood] See comments in the report
Clinical Significance	This test is conducted for the diagnosis, prognosis assessment, and treatment decision-making of myelodysplastic syndromes (MDS). DNA is extracted from bone marrow and blood to analyze mutation information in genes related to the disease. It is capable of detecting SNV (single nucleotide variants) and small indels (insertions/deletions), with a mutation detection sensitivity of approximately 5%. Additionally, it is highly sensitive in detecting FLT3-ITD mutations with low allele burden.
Remark

Reference range/Unit

 [Whole Blood]
See comments in the report

Clinical Significance

This test is conducted for the diagnosis, prognosis assessment, and treatment decision-making of myelodysplastic syndromes (MDS). DNA is extracted from bone marrow and blood to analyze mutation information in genes related to the disease.
It is capable of detecting SNV (single nucleotide variants) and small indels (insertions/deletions), with a mutation detection sensitivity of approximately 5%. Additionally, it is highly sensitive in detecting FLT3-ITD mutations with low allele burden.

Remark